The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1515
Kyleena - Another Hormonal IUD
The full article is available to subscribers Subscriber Login   

The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth levonorgestrel-releasing IUD to be approved in the US. Like Mirena, which has been available since 2000, Kyleena is approved for up to 5 years of use.

IUDs — IUDs provide convenient, long-term contraception and a rapid return to fertility after removal; they are considered safe for use in most women, including adolescents and nulliparous women.1 All levonorgestrel-releasing IUDs, which are approved for 3 or 5 years of use, can reduce menstrual bleeding and dysmenorrhea. Amenorrhea can occur, especially with devices that contain more levonorgestrel.2 ParaGard T380A, a copper-containing IUD, is FDA-approved for up to 10 years ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Kyleena - Another Hormonal IUD
Article code: 1515e
 Electronic, downloadable article - $25